Molecular Mechanisms of Brain Development and Psychiatric Diseases

A special issue of Brain Sciences (ISSN 2076-3425). This special issue belongs to the section "Molecular and Cellular Neuroscience".

Deadline for manuscript submissions: 15 May 2024 | Viewed by 2739

Special Issue Editors


E-Mail Website
Guest Editor
1. Department of Laboratory Animal Science, Fudan University, Shanghai 200032, China
2. State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Institutes of Brain Science, Fudan University, Shanghai 200032, China
Interests: corticogenesis; neuronal growth and maturation; genetically modified mice; axonal path-finding and extension; psychiatric disorders

E-Mail Website
Guest Editor
Department of Psychiatry, National Clinical Research Center and National Center for Mental Disorders , The Second Xiangya Hospital, Central South University, Changsha 410011, Hunan, China.
Interests: schizophrenia, depression, autism spectrum disorder, brain development

Special Issue Information

Dear Colleagues,

A growing number of large-scale molecular epidemiologic studies has strongly suggested shared mechanisms and pathways between brain development and psychiatric disorders. There is now an appreciation of the growing roles of DNA polymorphism, rare genetic mutation, de novo mutation, tandem repeats and retrotransposon elements which profoundly affect genome integrity and stability. These genetic variants work synergically with environmental stress and thus change the trajectory of neurodevelopment which may co-segregate with a range of psychiatric disorders.

In this Special Issue, we would like to provide a panoramic view of ongoing research covering new advances in genetic variants and molecular networks underpinning neurodevelopmental and psychiatric disorders. An interplay between neurodevelopment and mental health is preferred but not essential. We encourage a wide range of submissions including original articles, review papers, innovative research methods, etc.

Prof. Dr. Yuqiang Ding
Dr. Bing Lang
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Brain Sciences is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • genetic variants
  • neurodevelopment
  • psychiatric disorders
  • environmental stress
  • molecular mechanisms

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

21 pages, 1844 KiB  
Review
Rett Syndrome and the Role of MECP2: Signaling to Clinical Trials
by Adele Gaspar Lopes, Sampath Kumar Loganathan and Jayalakshmi Caliaperumal
Brain Sci. 2024, 14(2), 120; https://doi.org/10.3390/brainsci14020120 - 24 Jan 2024
Viewed by 2479
Abstract
Rett syndrome (RTT) is a neurological disorder that mostly affects females, with a frequency of 1 in 10,000 to 20,000 live birth cases. Symptoms include stereotyped hand movements; impaired learning, language, and communication skills; sudden loss of speech; reduced lifespan; retarded growth; disturbance [...] Read more.
Rett syndrome (RTT) is a neurological disorder that mostly affects females, with a frequency of 1 in 10,000 to 20,000 live birth cases. Symptoms include stereotyped hand movements; impaired learning, language, and communication skills; sudden loss of speech; reduced lifespan; retarded growth; disturbance of sleep and breathing; seizures; autism; and gait apraxia. Pneumonia is the most common cause of death for patients with Rett syndrome, with a survival rate of 77.8% at 25 years of age. Survival into the fifth decade is typical in Rett syndrome, and the leading cause of death is cardiorespiratory compromise. Rett syndrome progression has multiple stages; however, most phenotypes are associated with the nervous system and brain. In total, 95% of Rett syndrome cases are due to mutations in the MECP2 gene, an X-linked gene that encodes for the methyl CpG binding protein, a regulator of gene expression. In this review, we summarize the recent developments in the field of Rett syndrome and therapeutics targeting MECP2. Full article
(This article belongs to the Special Issue Molecular Mechanisms of Brain Development and Psychiatric Diseases)
Show Figures

Figure 1

Back to TopTop